MAIA Biotechnology (NYSE American: MAIA) has announced highlights from a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany, showcasing its ongoing Phase 2 and Phase 3 trials of ateganosine in non-small cell lung cancer (NSCLC).
In a statement, Vlad Vitoc, MD, CEO of MAIA, commented, “The posters showcased at ESMO 2025 featured exceptional extended survival in third-line NSCLC patients. In addition, as of September 17, 2025, a patient that began therapy in March 2023 has shown survival of 30 months, or 912 days, an outstanding measure relative to many of the high-risk cancers. Very few options exist for patients who are refractory or resistant to immune checkpoint inhibitors (ICI). We believe that a survival of over two years is a clear signal of ateganosine’s role in effectively targeting and eliminating NSCLC tumor cells.”
According to MAIA, the patient with 30-month survival received therapy every three weeks, and concluded treatment upon reaching the maximum treatment duration of 2 years based on protocol requirements.
